Efficacy of Locoregional Treatment for Oligo-Drug-Resistant Lesions during First-Line Atezolizumab plus Bevacizumab Therapy for Unresectable Hepatocellular Carcinoma: A Single-Center Retrospective Study
LRTs may provide a viable option for managing oligo-drug-resistant lesions during first-line atezo/bev therapy for unresectable HCC when safely administered.
Authors
- Katsuyuki Nakanishi
- Makiko Urabe (ORCID: https://orcid.org/0009-0009-8033-3158)
- Kana Hosokawa
- Yugo Kai
- Sena Higashi
- Toshiki Ikawa (ORCID: https://orcid.org/0000-0001-9097-0227)
- Ryoji Takada (ORCID: https://orcid.org/0000-0002-6568-8091)
- Kenji Ikezawa (ORCID: https://orcid.org/0000-0001-7517-8960)
- Kazuyoshi Ohkawa (ORCID: https://orcid.org/0000-0001-9700-2472)
- Tasuku Nakabori (ORCID: https://orcid.org/0000-0002-9486-850X)
- Kaori Mukai (ORCID: https://orcid.org/0000-0003-1043-4577)
- Masaki Kawabata
- Kazuhiro Kozumi
- Noboru Maeda
- Koji Konishi
Institutions
- Osaka International Cancer Institute (JP)
- Osaka International Cancer Institute (JP)
Publication Details
- Journal
- Oncology
- Published
- 2025-05-02
- DOI
- https://doi.org/10.1159/000546211
- Citations
- 1
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 1.32